about
N-acetylcysteine for non-paracetamol drug-induced liver injury: a systematic review protocolEvaluation of encapsulated liver cell spheroids in a fluidised-bed bioartificial liver for treatment of ischaemic acute liver failure in pigs in a translational settingHepatitis C treatment: where are we now?Ultra-deep sequencing reveals high prevalence and broad structural diversity of hepatitis B surface antigen mutations in a global populationDisseminated Emmonsia in an HIV-HBV co-infected man.N-acetylcysteine for non-paracetamol drug-induced liver injury: a systematic review.Hepatitis E virus: Western Cape, South Africa.Challenges for paediatric transplantation in Africa.Health disparities in liver disease in sub-Saharan Africa.World Gastroenterology Organisation Global Guideline Hepatitis B: September 2015.The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - volume 2.DNA Oncogenic Virus-Induced Oxidative Stress, Genomic Damage, and Aberrant Epigenetic AlterationsMolecular characterisation of acute intermittent porphyria in a cohort of South African patients and kinetic analysis of two expressed mutants.Identification of a novel and severe pattern of efavirenz drug-induced liver injury in South Africa.A clinicopathological cohort study of liver pathology in 301 patients with human immunodeficiency virus/acquired immune deficiency syndrome.Strategies to manage hepatitis C virus (HCV) infection disease burden - volume 2.Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 2.Preventing hepatitis B and hepatocellular carcinoma in South Africa: The case for a birth-dose vaccine.Hepatitis C in sub-Saharan Africa: the current status and recommendations for achieving elimination by 2030.Hepatitis B in sub-Saharan Africa: strategies to achieve the 2030 elimination targets.A clinical-scale BioArtificial Liver, developed for GMP, improved clinical parameters of liver function in porcine liver failure.Effect of liver regeneration on the pharmacokinetics of immunosuppressive drugs.The effect of rapamycin on the healing of the ureteric anastomosis and wound healing.A novel high molecular weight fibrinogenase from the venom of Bitis arietans.Immune tolerance and immunosuppression in solid organ transplantation.Hepatitis B in rugby: is it time to revisit policy?Impact of viral infections on organ donation in South AfricaExtended hepatic resection with transplantation back-up for an "unresectable" tumourThe Budd-Chiari syndrome in children: the spectrum of managementA novel 25 kDa protein from the venom of Bitis arietans with similarity to C-type lectins causes fibrinogen-dependent platelet agglutinationThe expression of MUC mucin in cholangiocarcinomaAuthors' reply
P50
Q27014948-E0FE8750-4848-4678-BFD5-12538D2090D2Q27300507-FFC643DD-8C77-4C3D-8CC0-EEB72B267C35Q30378509-8D0C723D-4DBA-4509-89A2-037A79366B22Q33637292-F66B639C-B979-4022-9F3F-3CA6474DD2EEQ36354431-25C536B6-D64B-47EE-AB45-ECFEE928D81DQ36924709-EB4161B8-DC26-4B51-B302-24A6095BB654Q37444294-EA57EE7F-2481-4B19-BB5C-160113DB1B2FQ38239455-40E0976E-9534-4300-BC17-3C500B987E98Q38520338-E6CDD1ED-6EFF-4CA9-9896-20A28019EEA3Q38953335-4A7AFC5A-0848-40A6-8484-982F96F92E8BQ39064153-ACB1D976-95AD-4CD9-92A0-4F67AEE40337Q39455821-F0F985C6-0AC7-4D9E-91B8-63B809F8ED91Q40473899-35D720DE-5FFF-4FA1-8CB1-15C3E1CDB42DQ40761852-535AE72C-283F-4821-87A7-F4A390D2D73EQ41490253-479F2CBE-0E0F-46DD-B3AD-BFED76A7B346Q41562296-2814908D-3C72-48DE-B31A-8FE299D7B5AAQ41562307-95C9B3CE-564D-42EB-ABB5-01A7CB836250Q41742737-DDDC3F43-FA09-46C7-867A-A3E962B4AA67Q43923983-60E3C64B-DF4E-4E3F-99E7-5EF1F5628B41Q43923988-CAE49E01-56EC-443A-9624-CD0793A6523CQ45978445-EA311A21-EC62-41CE-92A7-DB19BED6BADAQ46105818-D688D992-7BB4-496B-B7C4-14B0DE868D61Q46452744-ABF664F6-D52D-40E7-9CB9-59CD5A1E21E7Q47269577-1ECA338C-FAEF-4BB1-B80E-51EEAF5FAD9BQ49570130-751191B9-A1E2-4C8B-BF73-A70D6E6BCDC0Q50940264-0428524F-328C-403C-8677-98763645E59CQ73983792-984ACFE5-18FC-457C-9CC5-E2EC87558F88Q74437489-18F21EB0-576D-4092-A26F-AD06EB8AF8B3Q79353996-DBD312F1-FEBD-499F-962C-869D99AA5A2CQ81228221-D088A668-7DE2-4093-8950-A82533119927Q85195886-2B385D8B-B40D-431C-8726-0ADB7FFB9AFBQ88038380-9A3B36DB-E650-443E-A8C5-0A38A1BF8817
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Catherine Wendy Spearman
@ast
Catherine Wendy Spearman
@en
Catherine Wendy Spearman
@es
Catherine Wendy Spearman
@nl
Catherine Wendy Spearman
@sl
type
label
Catherine Wendy Spearman
@ast
Catherine Wendy Spearman
@en
Catherine Wendy Spearman
@es
Catherine Wendy Spearman
@nl
Catherine Wendy Spearman
@sl
prefLabel
Catherine Wendy Spearman
@ast
Catherine Wendy Spearman
@en
Catherine Wendy Spearman
@es
Catherine Wendy Spearman
@nl
Catherine Wendy Spearman
@sl
P106
P1153
6602099397
P21
P31
P496
0000-0003-3199-301X